PDCD1 and neoplasm: For the secondary tumor treatment, 1 day after the administration of LIT (Figure 7B), the combination of LIT with anti-PD-1 showed synergistic antitumor effects by decreasing the expression of PD-L1 on the surface of tumor cells and reversing dysfunction of CTLs.